Alexandra J. Livingstone
Research Subjects
Alexandra J. Livingstone has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Albert H. Kim
Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, USA
500 shared publications - Gavin P. Dunn
Department of Neurosurgery, Massachusetts General Hospital, Boston, USA
500 shared publications - Gregory Joseph Zipfel
Department of Neurosurgery, Washington University School of Medicine, St. Louis, Missouri, USA
500 shared publications - Michael R. Chicoine
Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri
500 shared publications - Tanner M. Johanns
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
500 shared publications - Elaine R. Mardis
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, USA
498 shared publications
Latest Publications
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
PVAC-Seq predicted neoantigens for each subject and each tumor region from whole exome sequencing data
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
PVAC-Seq predicted neoantigens for each subject and each tumor region from whole exome sequencing data
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
ImmunoSEQ resolved TCR sequences for each subject PBMCs pre- and post-NeoVax
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
ImmunoSEQ resolved TCR sequences for each subject PBMCs pre- and post-NeoVax
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Bar graph displaying number of validated variants for each subject
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Bar graph displaying number of validated variants for each subject
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
CDR3beta sequences ranked by ratio
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
CDR3beta sequences ranked by ratio
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Mutect2 called and validated variants for each subject and each tumor region from whole exome sequencing data
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Mutect2 called and validated variants for each subject and each tumor region from whole exome sequencing data
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
CIBERSORTx relative percents of deconvoluted immunocytes
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
CIBERSORTx relative percents of deconvoluted immunocytes
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Representativeness of study participants
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Representativeness of study participants
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
RNA-sequencing pseudo counts generated via Salmon algorithm
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
RNA-sequencing pseudo counts generated via Salmon algorithm
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Immunohistochemistry (IHC) quantification of CD3+ and CD8+ T cells from tumor blocks
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Immunohistochemistry (IHC) quantification of CD3+ and CD8+ T cells from tumor blocks
- Open Access
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Differential expression analysis of nCounter CAR-T characterization panel gene expression analyzed via ROSALIND software
- 19 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma
Differential expression analysis of nCounter CAR-T characterization panel gene expression analyzed via ROSALIND software